Gilead Sciences logged a -0.1% change during today's evening session, and is now trading at a price of $75.62 per share. On average, analysts give it a target price of $91.04.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The large-cap company is based in the United States. Gilead Sciences currently returns an annual dividend yield of 3.9%.
What to Consider if You Are Thinking of Buying Gilead Sciences:
-
Gilead Sciences has moved 17.0% over the last year.
-
GILD has a forward P/E ratio of 10.4 based on its EPS guidance of 7.24.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 3.6%.
-
The company has a price to earnings growth (PEG) ratio of 2.58.
-
Its Price to Book (P/B) ratio is 4.46
Gilead Sciences Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-22 | 9,072,000 | -728,000 | 9,800,000 | -18.08 |
| 2022-02-23 | 11,384,000 | -579,000 | 11,963,000 | 35.67 |
| 2021-02-25 | 8,168,000 | -650,000 | 8,818,000 | -11.55 |
| 2020-02-25 | 9,144,000 | -825,000 | 9,969,000 | 6.92 |
| 2019-04-18 | 8,400,000 | -924,000 | 9,324,000 | -25.34 |
| 2018-02-27 | 11,898,000 | -590,000 | 12,488,000 |
Gilead Sciences's free cash flows have a decent average of $10.39 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 71914138052.2%. The compounded average growth rate over this period is 0.0%.
